Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Actuate Therapeutics Inc.
AstraZeneca
Aminex Therapeutics, Inc.
Nuvation Bio Inc.
BBB-Therapeutics B.V.
INSYS Therapeutics Inc
Envita Medical Center, Inc.
TransMolecular
Thallion Pharmaceuticals